OncoMatch/Clinical Trials/NCT07144384
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Is NCT07144384 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Natural Killer Cell Therapy and Universal Donor Expanded TGF-beta-imprinted NK Cells for skin basal cell carcinoma.
Treatment: Natural Killer Cell Therapy · Universal Donor Expanded TGF-beta-imprinted NK Cells — This early phase I trial compares the safety, side effects and the biological or cellular activity of two types of universal donor (UD) natural killer (NK) cells (standard NK cells and transforming growth factor \[TGF\] beta imprinted \[TGF-beta-i\] NK cells), given directly into the tumor (intratumoral) in treating patients with skin (cutaneous) squamous cell carcinoma (SCC) or basal cell carcinoma (BCC). NK cells are a type of white blood cell that can recognize missing or incorrect proteins on tumor cells and then kill these tumor cells. It was recently discovered that infection with human cytomegalovirus (CMV), a common virus, leads to the development of a unique NK cell population. These "adaptive" NK cells have a more potent anti-tumor killing action. The TGF-beta-i NK cells used in this study are created using donors whose blood tests positive for CMV exposure. This may make them more effective at killing tumor cells. Giving UD TGF-beta-i NK cells may be safe, tolerable and/or more effective than standard UD expanded NK cells in treating patients with SCC or BCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Excluded: Stage SCC IN SITU (SCCIS)/BOWEN DISEASE, > T2
SCC: Well-differentiated or aggressive subtype with T1 or T2 staging by American Joint Committee on Cancer (AJCC) criteria
Prior therapy
Cannot have received: radiation therapy
Planned or concurrent radiation ... for solid tumor or hematologic malignancy including chemotherapies or immunotherapies received within 6 weeks of trial enrollment
Cannot have received: systemic chemotherapy (methotrexate, 5-fluorouracil)
chemotherapies ... received within 6 weeks of trial enrollment. These include but are not limited to methotrexate, 5-fluorouracil
Cannot have received: hedgehog pathway inhibitor (vismodegib)
These include but are not limited to ... vismodegib
Cannot have received: immunotherapy (cepilimumab, pembrolizumab, nivolumab, ipilimumab)
These include but are not limited to ... cepilimumab, pembrolizumab, nivolumab, ipilimumab for any skin malignancy
Cannot have received: investigational drug
Patients who received any other investigational drugs within the 30 days prior to screening visit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify